Form 8-K - Current report:
SEC Accession No. 0001193125-25-098817
Filing Date
2025-04-28
Accepted
2025-04-28 09:49:42
Documents
13
Period of Report
2025-04-24
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d935409d8k.htm   iXBRL 8-K 22592
  Complete submission text file 0001193125-25-098817.txt   143511

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tpst-20250424.xsd EX-101.SCH 2856
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tpst-20250424_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tpst-20250424_pre.xml EX-101.PRE 11265
15 EXTRACTED XBRL INSTANCE DOCUMENT d935409d8k_htm.xml XML 3637
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35890 | Film No.: 25876630
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)